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Background: The aim of study was to evaluate the oral health status, salivary flow and halitosis among individuals 
diagnosed with leprosy as compared with healthy subjects. 
Material and Methods: A sample of 160 individuals was allocated into four groups, as follows: (G1) individuals 
with complete leprosy treatment; (G2) individuals diagnosed with leprosy and under multi-drug therapy; (G3) 
individuals diagnosed with leprosy not yet under treatment; and (G4) healthy individuals. Then individuals were 
submitted to periodontal clinical examination (visible plaque index, bleeding index, depth of probing and clinical 
attachment level); DMFT index (decayed-missing-filled teeth index); evaluation of salivary flow and halitosis us-
ing a halimeter equipment (Interscan Corp, Chatsworth, CA, USA). 
Results: The data were analyzed using Kruskal-Wallis and chi-square tests. The mean DMFT was found to be 
higher than 6.6, which is considered very high, with no significant difference between groups (P>0.05). As for 
salivary flow, 76.2% of the subjects presented normal flow rates, while 10% and 13.7% showed low and very low 
salivary flow rates, respectively, with hyposalivation being mostly observed in Groups 1 and 2. The highest preva-
lence of noticeable odor was found in healthy individuals (G4), and the most prevalent periodontal diagnosis was 
gingivitis (63.1%) in Group 3 (individuals with leprosy not yet under multi-drug therapy) followed by periodontitis 
(25%) in Group 1 (individuals who had completed leprosy treatment). 
Conclusions: It was observed that individuals with a history of leprosy present poor oral health similar to that of 
systemically healthy individuals.
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Introduction
Leprosy is a chronic granulomatous infectious disease 
caused by Mycobacterium leprae, which presents with 
slow evolution with skin, peripheral nerve, and mucous 
membrane tropism (especially the respiratory tract) and 
has high infectivity and low pathogenicity (1).
Mato Grosso, located in the Midwest region of Brazil, 
is part of the Brazilian Amazon. This region has high 
leprosy detection rates and was classified, according to 
the parameters of the Ministry of Health ordinance MS/
GM N. 3125 of October 7, 2010, as hyperendemic. This 
region has the highest prevalence of any Brazilian state: 
10.19 cases/10,000 inhabitants (2,3).
The clinical forms of leprosy are classified according 
to the interactions of M. leprae with the host immune 
response (2). The Madrid classification consists of clini-
cal and bacilloscopic characteristics, dividing leprosy 
into two immunologically unstable groups, i.e., inde-
terminate and borderline, and two stable polar types, 
i.e., tuberculoid and lepromatous. The Ridley & Jopling 
characterisation is based on clinical, bacilloscopic, im-
munological and histopathological criteria (1-3).
In 1982, the World Health Organization (WHO) pro-
posed a simplified classification based on clinical mani-
festations and bacilloscopy in which cases with five or 
fewer skin lesions were considered paucibacillary (PB), 
whereas those with more than five skin lesions were 
considered multibacillary (MB) (2). This determina-
tion was crucial for the selection of drug therapy, and 
it reduced misdiagnoses, disease reactivation and even 
secondary resistance (2). 
The upper airways are the most important gateway to 
the bacillus and the main source for bacillary elimina-
tion in leprosy. The oral mucosa is likely the second 
major site of M. leprae infection and transmission, and 
it plays a fundamental role in the transmission of adult 
leprosy to children. Several anatomic sites affected by 
leprosy and the most commonly affected regions of the 
oral cavity are the hard palate, soft palate, uvula, lips, 
tongue, and gingiva as well as the anterior region of the 
maxilla, which shows significant bone erosion and den-
tal loss (3,4).
Periodontal diseases (PDs) are highly prevalent among 
adults. PDs consist of an inflammatory process of in-
fectious origin, wherein the dental biofilm plays an im-
portant role in the process of pathogenicity, causing the 
destruction of the tooth support tissue. In addition to 
the appearance of periodontal pockets, insertion loss, 
inflammation, and the degradation of soft tissues, hali-
tosis is a consequence of PD. The intraoral etiological 
factors of bad breath are associated with the presence of 
tongue coating in 85% to 90% of cases (5).
Halitosis is a breath alteration condition that is unpleas-
ant for both the patient and those with whom the patient 
interacts. Because a social life is one of the pillars of 
quality of life, it is necessary to consider halitosis as a 
factor of negative interference that might denote a path-
ological condition (4,5).
Currently, caries and its consequences (obturation and 
tooth loss) are pathologies that are highly prevalent in 
the population and affect individuals across different 
age groups. Thus, caries has been a constant concern of 
the institutions responsible for evaluating and promot-
ing measures to improve population health. The decay, 
missing, filled (DMF) index has been widely used in ep-
idemiological surveys of oral health. The World Health 
Organization (WHO) recommends that this index be 
used to measure and compare the dental caries experi-
ence within populations. Its value expresses the average 
number of decayed, lost, and obturated teeth in a group 
of individuals (6,7).
Many factors, such as salivary gland origin, diet, the 
use of pharmacological agents, and the oral and system-
ic health of the individual, might affect composition and 
salivary flow (8).
Some of the several side effects of polychemotherapy 
(PCT) for leprosy include dry skin and mucous mem-
branes, gastrointestinal disorders (e.g., abdominal and 
epigastric pain, diarrhea, nausea, vomiting, gastrointes-
tinal intolerance), and changes in excretions (e.g., urine 
and feces) and secretions (e.g., sweat and saliva) (9,10).
A variety of oral changes have been associated with 
the hypofunction of the salivary glands, including in-
creased dental caries, PD, mucositis, angular cheilitis, 
and an altered sense of taste. Most efforts to diagnose 
salivary gland hypofunction include salivary flow mea-
surements (11).
Thus, despite the literature demonstrating the oral health 
profile of patients with leprosy through DMF indices, 
a significant gap exists in the knowledge concerning 
the oral profile before, during, and after treatment us-
ing PCT. Therefore, the current research evaluated oral 
health condition, salivary flow, and halitosis across the 
different stages of leprosy treatment and compared the 
results with those of healthy individuals.
Material and Methods
The present observational study was approved by the 
Ethics and Research Committee of the University of 
Cuiabá (Process n. 281.921) in compliance with Reso-
lution 196/96 of the National Health Council. Only the 
eligible individuals who agreed and signed the Free and 
Informed Consent Document participated in this study. 
The populations of this study consisted of individuals 
diagnosed with leprosy and treated at the Júlio Muller 
University Hospital in Cuiabá, Mato Grosso, Brazil 
and systemically healthy individuals from the primary 
healthcare units of Cuiabá (MT, Brazil). Individuals 
were eligible for this study if they were over 18 years of 
age and not pregnant. For inclusion in the diagnosed but 
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untreated group, participants should not have started 
medication. Individuals with mouth opening limita-
tions preventing clinical examination, those who were 
immunosuppressed (HIV or transplanted), and those 
without a definitive diagnosis of leprosy were excluded 
from this study.
The convenience-based sample was composed of 160 
individuals divided into four groups: Group 1 was 
composed of individuals who had already completed 
leprosy treatment (n = 40); Group 2 was composed of 
individuals with leprosy receiving PCT (n = 40); Group 
3 was composed of individuals diagnosed with leprosy 
who had not begun treatment (n = 40); and Group 4 was 
composed of healthy individuals (n = 40). The following 
individual data were recorded: sex, age, family income, 
oral hygiene habits, and self-perception of oral health. 
The individuals were randomly selected based on the 
demands of the hospital and health unit.
-Clinical Evaluation
The intraoral physical examination was performed 
without prior prophylaxis or supervised brushing. To 
establish a diagnosis, the participants underwent com-
plete periodontal examination with the aid of a mouth 
mirror and a manual periodontal probe (PCPUNC 15 
Hu-Friedy®, Mfg Co Inc. Chicago, IL, USA), and the 
data were recorded in a periodontal file. The clinical 
parameters evaluated included the visible plaque in-
dex (VPI) and gingival bleeding index (GBI). Both the 
VPI and GBI are dichotomous examinations; the first 
examination checks for the presence of dental plaque, 
and the second checks for gingival inflammation (12). 
Probing depth (PD) and clinical insertion level (CIL) 
were evaluated in mm at six dental sites: mesiobuccal, 
buccal, distobuccal, mesiolingual, lingual, and distolin-
gual. The third molars were not evaluated. PD refers to 
the distance in mm between the gingival margin and the 
bottom of the gingival groove/pocket. The CIL is the 
distance in mm between the cemento-enamel junction 
and the bottom of the gingival groove/pocket. 
After the evaluation of the clinical parameters, a peri-
odontal diagnosis was established: periodontal health 
denoted < 30% of the periodontal sites presented with 
gingival bleeding; gingivitis denoted > 30% of the peri-
odontal sites presented with gingival bleeding; peri-
odontitis denoted the presence of four or more teeth 
with one or more sites with PD ≥ 4 mm and with a loss 
of clinical insertion of ≥ 3 mm at the same site (12).
The DMF index was used to record elements classified 
as decay (code 1), filled (code 2), or missing (code 3) 
teeth that were indicated for extraction (code 4). Healthy 
teeth (code 5) were also classified. Subsequently, all of 
the elements involved were summed and divided by the 
number of individuals examined (7).
A single examiner previously calibrated according to 
the methodology described by Araújo et al. (13), ob-
tained each clinical parameter. The standard error of 
the measurement (SEM) was used to describe the con-
tinuous variable (i.e., PD), and the Kappa test was used 
for the categorical variables (i.e., VPI, GBA, and DMF). 
Thus, ten tests were repeated within 30 days and sub-
mitted to analysis. The examiner was considered as 
calibrated based on the following scores: SEM ≤ 0.8 as 
well as K > 0.8 and < 0.95. 
-Salivary Flow
Salivary flow was evaluated via the stimulation of sa-
liva with a block of Parafilm® (Bemis NA, Chicago, IL, 
USA) and measured according to the recommendations 
of Flink et al. (14). After receiving a 20-ml wide-mouth 
vial, participants sat relaxed in front of the examiner, 
keeping their mouth open and their tongue positioned 
on the palatal surface of the upper incisors. Then, par-
ticipants chewed Parafilm® for 2 minutes to stimulate 
salivation. Next, they spit all of the saliva formed into 
the vial. At exactly 5 minutes (timed by the examiner), 
the patient spat for the last time. The total volume of 
saliva collected in 5 minutes was checked, excluding 
foam. The final value was divided by five, and the sali-
vary flow result obtained in ml/min was recorded in the 
clinical file. The stimulated salivary flow rate was con-
sidered as normal for values between 1.0 and 3.0 ml/
min (15).
-Evaluation of Halitosis
Halitometry was performed using the Halimeter® 
(Interscan Corp, Chatsworth, CA, USA) apparatus in 
which a disposable straw was connected to the device 
and placed approximately 4 cm in the posterior region 
of the mouth to evaluate the presence or absence of vol-
atile compounds with a strong odor.
The patient remained with semi-open lips, without 
breathing for 15 seconds, and the value displayed on 
the equipment during the maximum peak was recorded, 
which represented the concentration of oral volatile sul-
fur compounds (VSCs). The individuals then exhaled 
their pulmonary air to detect the presence of systemic 
VSCs (16).
The VSC results were interpreted according to the 
manufacturer’s instructions: less than 80 ppb denoted 
no perceptible odor, 80 to 100 ppb denoted perceivable 
odor, 100 to 120 ppb denoted moderate halitosis, 120 to 
150 ppb denoted more pronounced halitosis, and > 150 
ppb denoted severe halitosis.
Results
The individuals evaluated were between 18 and 78 years 
old, and Group 1 (individuals who already completed 
leprosy treatment) showed a higher mean age (48.9 
years), followed by Group 2 (leprosy patients receiv-
ing PCT; 45.7 years), Group 3 (individuals diagnosed 
with leprosy who had not begun treatment; 44.1 years), 
and Group 4 (healthy individuals; 37.3 years). Of these 
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patients, 57.5% were men, and 41.2% were mestizo, fol-
lowed by 38.1% black and 20.7% white (p = 0.0386, chi-
square test). Education, 42.5% had completed between 
the 5th and 9th grade. The results demonstrated signifi-
cant inter-group differences (p < .0001, chi-square test). 
Additionally, socioeconomic status, 59.3% of the indi-
viduals reported receiving from 1 to 3 minimum wages 
within their families. One hundred and ten cases met 
the operational classification for multibacillary leprosy 
(91.6%) and ten paucibacillary (8.4%).
Regarding tobacco use, 56.8% of the participants re-
ported not being smokers, and 21.8% reported being 
ex-smokers. Notably, oral hygiene 91.2% of respondents 
said that they brushed their teeth, and 41.2% said they 
brushed three or more times per day. The flossing, 60% 
did not floss; however, of those who reported flossing, 
20% reported flossing twice a day. Tongue hygiene, 
75% reported brushing their tongues. However indi-
viduals’ self perceptions of oral problems, 62.5% said 
they did not feel or have bad breath, 48.1% stated that 
they did not perceive halitosis. At the time of the present 
study, the presence of gingival bleeding, 54.3% report-
ed no bleeding, 23.2% reported that their gums bled, 
and 22.5% stated that sometimes the gingiva presented 
with bleeding (Table 1).
In the dental clinic evaluation, the mean DMF index 
score was > 6.6 for all groups, which is considered high 
according to the Ministry of Healthd. Group 1 had the 
highest mean DMF (17.05), followed by Group 4 (16.3); 
however, Group 2 (14.8) and Group 3 (14.2) presented 
with approximately equal values. Thus, the inter-group 
evaluation did not reveal significant differences (p > 
0.05). The evaluation of salivary flow, 76.2% presented 
with normal salivary flow, 10% of the individuals had 
low salivary flow, and 13.7% had very low salivary flow. 
The individuals who presented with the most hyposali-
vation belonged to Groups 1 and 2. The results showed 
significant differences (p = 0.0012) between groups 
(Table 2).
For the halitosis test, 43.7% of the individuals presented 
with a noticeable odor, 35.6% presented with no notice-
able odor, 2.5% presented with pronounced halitosis, 
and 1.2% had severe halitosis. A high concentration 
of Group 4 individuals had halitosis, and a significant 
difference (p = 0.0067) was observed between groups 
(Table 2).
In the periodontal clinical diagnosis, 63.1% of the indi-
viduals presented with gingivitis, 25% presented with 
periodontitis, and 6.2% showed gingival health. No sig-
nificant difference (p > 0.05) was found between groups 
(Table 1). About the periodontal clinical parameters 
GBI, VPI, CIL, and PD, the Kruskal-Wallis test used 
for intergroup analysis did not reveal a significant dif-
ference (p > 0.05; Tables 3,4).
Discussion
Leprosy is an age-old disease that affects modern popula-
tions mainly located in India and Brazil. This disease con-
tinues to have a significant global impact, with official re-
ports from 121 countries. According to the WHO, 213,899 
newly diagnosed cases were recorded in 2014 (17).
The present study observed a mean participant age of 
44.1 years. At this age, the individual is considered as 
economically active and productive, and the sequelae of 
leprosy due to late diagnosis can affect the lives of these 
individuals, isolating them from social interactions and 
making it impossible for them to exercise their normal 
work activities because of upper limb atrophy, which 
might even cause oral hygiene limitations (18).
The present study identified a predominance of mestizo 
individuals in all groups (41.2%), which corroborates 
the results of other studies (19,20).
Concerning the education level, the majority (42.5%) had 
completed elementary school. Furthermore, to income, 
the study showed a predominance of one to three mini-
mum wages in all groups. According to some authors, 
populations with lower socioeconomic statuses have dif-
ficulty accessing dental services, which leads to poorer 
dental conditions and possible outbreaks of oral cavity 
infections (19,20). The transmission of leprosy is influ-
enced by socioeconomic conditions, nutritional status, 
genetic conditions, and concomitant infections (21). 
No significant difference between groups was found to-
bacco use; most of the individuals, regardless of group, 
were non-smokers, and the smoker distribution was 
homogeneous. Although smoking is a risk factor for 
PD and favors its progression, in the present study, this 
variable did not show a specific negative interference 
for any group, regardless of the diagnosis of leprosy. 
This response is most likely related to the small number 
of smokers (22).
Concerning to oral hygiene, dental brushing, and how 
many times a day the individual brushes his or her teeth, 
the majority of individuals within the studied groups re-
ported brushing their teeth three times a day or more. 
However, the quantity of brushing should be associated 
with its quality (23), and the present study negatively 
verified this result given the high rate of PD and conse-
quent halitosis (noticeable odor and moderate halitosis), 
even among the systemically healthy group. A signifi-
cant difference was observed for dental flossing (p = 
0.0129) in which most individuals did not use dental 
floss; when they did, they reported using it twice a day 
or more, regardless of the group studied. Although the 
systemically healthy group flossed more frequently than 
the other groups, the non-use of dental floss is justified 
by its financial (socioeconomic conditions) and cultural 
(education) associations.
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Variable Category Group Total p-value 
Chi-Square 
Test 
1 2 3 4 
Smoker Yes 8 10 10 6 34 0.0532 
24 29 29 18 
Not 25 16 20 30 91 
27 18 22 33 
Ex smoker 7 14 10 4 35 
20 40 29 11 
Brushing teeth Toothless 5 4 0 0 9 0.1049 
56 44 0 0 
Yes 34 34 39 39 146 
23 23 27 27 
Not 1 2 1 1 5 
20 40 20 20 
How often do you 
brush your teeth 
Not rated 6 6 1 1 14 0.0758 
43 43 7 7 
1 time 7 3 7 4 21 
33 14 33 19 
2 times 16 17 10 13 56 
29 30 18 23 
3 or more times 11 14 22 22 69 
16 20 32 32 
Floss Not rated 5 4 0 0 9 0.0129 
56 44 0 0 
Yes 10 11 13 21 55 
18 20 24 38 
Not 25 25 27 19 96 
26 26 28 20 
How often do you floss Not rated 30 28 27 19 104 0.446 
29 27 26 18 
1 time 0 6 2 4 12 
0 50 17 33 
2 times 9 4 8 11 32 
28 13 25 34 
3 or more times 1 2 3 6 12 
8 17 25 50 
Brush your tongue Yes 29 28 30 33 120 0.6005 
24 23 25 28 
Not 11 12 10 7 40 
28 30 25 18 
Bad taste in the mouth Yes 16 14 16 14 60 0.9347 
27 23 27 23 
Not 24 26 24 26 100 
24 26 24 26 
Halitosis Yes 7 10 10 16 43 0.1435 
16 23 23 37 
Not 26 19 19 13 77 
34 25 25 17 
Sometimes 7 11 11 11 40 
18 28 28 28 
Gum bleeds Yes 9 8 6 14 37 0.1696 
24 22 16 38 
Not 26 23 22 16 87 
30 26 25 18 
Sometimes 5 9 12 10 36 
14 25 33 28 
Table 1: Habits and perception of oral health of groups of individuals diagnosed with leprosy and control group.





Variable Category Group Total p-value Chi-
Square Test 1 2 3 4 
Classification  DMF Very tall (6 or more) 40 40 40 40 160  
25 25 25 25 
Salivary classification Normal 23 28 39 32 122 0.0012 
19 23 32 26 
Low 7 3 1 5 16 
44 19 6 31 
Very low 10 9 0 3 22 
45 41 0 14 
Halitosis No noticeable odor 19 18 17 3 57 0.0067 
33 32 30 5 
Perceive odor 13 17 13 27 70 
19 24 19 39 
Emit halitosis 6 3 8 10 27 
22 11 30 37 
Pronounced halitosis 1 2 1 0 4 
25 50 25 0 
Severe halitosis 1 0 1 0 2 
50 0 50 0 
Periodontal diagnosis Not rated 5 4 0 0 9 0.0610 
56 44 0 0 
Gingivitis 20 21 29 31 101 
20 21 29 31 
Periodontitis 13 12 9 6 40 
33 30 23 15 
Health 2 3 2 3 10 
20 30 20 30 
Total 40 40 40 40 160  
Table 2: Classification of DMF, salivary, halitosis and periodontal diagnosis of the groups of individuals diagnosed with leprosy and control 
group.
Group GBI VPI
Mean Median Standard 
deviation
Mean Median Standard 
deviation
Group 1 0.5 0.4 0.4 0.8 1.0 0.4
Group 2 0.5 0.4 0.4 0.8 1.0 0.3
Group 3 0.6 0.6 0.4 0.8 1.0 0.3
Group 4 0.4 0.2 0.4 0.7 0.6 0.3
p-value Kruskal-Wallis 0.2809 0.3301
Table 3: Mean, median and standard deviation of GBI and VPI per group.
Group CIL PD
Mean Median Standard 
deviation
Mean Median Standard 
deviation
Group 1 2.2 1.5 1.5 2.2 2.1 0.5
Group 2 2.0 1.5 1.1 2.1 2.0 0.6
Group 3 1.7 1.2 1.0 2.2 2.2 0.5
Group 4 1.5 1.2 0.7 2.1 2.0 0.4
p-value Kruskal-Wallis 0.0743 0.2911
Table 4: Mean, median and standard deviation of CIL and PD by group.
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Concerning tongue cleanliness, the majority (75%) of 
individuals reported cleaning their tongues; however, 
other studies have reported that the efficient cleaning of 
the tongue daily reduces halitosis through microbial re-
duction on its surface via a toothbrush or scrapers (5,8), 
Although individuals reported tongue cleaning in the 
present study, the high halitosis results indicate a defi-
ciency in this cleaning.
A lack of self-perceptions of oral health was verified by 
the most of the individuals (62.5%) reported no percep-
tion of bad taste in the mouth, bad breath (48.12%), or 
gingival bleeding (54.37%). Thus, the perception and 
knowledge of the individual upon what is pathological 
or physiological is somewhat complex because PD has 
a slow and progressive evolution. Often, the individual 
feels that a bad taste in the mouth or bad breath are per-
sonal traits or that result from gastric problems. Gum 
bleeding is also believed to result from harder foods or 
mechanical trauma due to the incorrect use of a tooth-
brush or floss (24-26).
Similar to the average found by Núnez-Martí et al., all 
groups presented a high score of DMF index (> 6.6), 
and no significant difference was found between groups 
of individuals diagnosed with leprosy and healthy indi-
viduals with regard to DMF (27).
In the present study, periodontal condition was exhib-
ited in all individuals of groups with gingivitis (63.1%); 
periodontitis (25%) and only 6.25% presented with gin-
gival health. These results corroborate those of Souza 
et al. (24), who used a periodontal clinical examination 
to diagnose approximately 80 to 88% of patients with 
PD. When comparing the results of patients diagnosed 
with leprosy and healthy individuals, the findings were 
similar: Both presented with poor oral health status, a 
finding that was also observed in the present study.
Approximately 43.7% of the individuals presented a no-
ticeable odor on the halitosis test. Strangely, a  higher 
prevalence of halitosis (noticeable odor) was observed 
in Group 4, even in a normal flow of saliva,  however 
this result is justified by the presence of dental biofilm 
found in the majority of this group presented with gin-
givitis, moreover an oral microbiota not altered by the 
non use of medicines, in case polychemotherapies and 
in agreement with some authors (5,9,11), no severe or 
pronounced halitosis was found in Group 4. Halitosis 
may occur as a consequence of decreased oral clearance 
due to bleeding or as a result of dental and oral mucosal 
disease (5,16).
Severe or pronounced halitosis was verified in Groups 
1, 2, and 3, which were related to leprosy and coincided 
with low and very low salivary flows in Groups 1 and 
2, respectively. This fact raises a question about the ca-
pacity of the drugs ingested to treat leprosy (dapsone, 
rifampicin, and clofazimine) to alter (modifiy) salivary 
flow, in addition to systemic and local changes, might 
manifest side effects in the oral cavity according to 
Femiano et al. wich reported that more than 500 medi-
cations that are currently in use produces sides effects; 
however, in the majority of cases, the mechanisms are 
unknown (5,6,11,28). 
The present study excluded the relationship between 
halitosis and the destruction of oral structures (e.g., per-
foration of the palate) as a consequence of leprosy. This 
finding leads us to believe that leprosy campaigns have 
helped to avoid its late diagnosis and advanced stages 
of the disease.
Many studies have examined the diagnosis and treat-
ment of leprosy, but few have addressed oral involve-
ment in leprosy. Cortella et al. (29) and Fucci da Cos-
ta et al. (23) stated that the oral cavity inflammatory 
process, either via dental infection or PD, can lead to 
leprosy reactions that are acute inflammatory processes 
secondary to the release of antigens and hypersensitiv-
ity reactions. These reactions are extremely deleterious 
and can lead to irreversible sequele among patients with 
leprosy.
Given the magnitude of leprosy with regard to public 
health and the high prevalence of the disease in Brazil, 
it should be discussed more often in dentistry cours-
es because the upper airways are the most important 
entryway of the bacillus, and the face is a location of 
broad disease onset.
The evaluation of the oral condition of individuals diag-
nosed with leprosy and healthy individuals allowed us 
to conclude the following:
•The DMF index was high for all groups, with a higher 
prevalence in Group 1 (individuals who had already 
completed leprosy treatment).
•Salivary flow was normal in 76.2% of individuals, with 
a higher prevalence of hyposalivation in Groups 1 (indi-
viduals who had already completed leprosy treatment) 
and 2 (patients with leprosy receiving PCT). This find-
ing leads us to consider the possible influence of a medi-
cation such as PCT on salivary flow.
•Concerning halitosis, noticeable odor showed the high-
est prevalence (43.7%) in Group 4 (healthy individu-
als), with a significant difference between groups (p = 
0.0067).
•In the periodontal diagnosis, most individuals present-
ed with some type of PD, with gingivitis being the most 
prevalent (63.1%) in Group 3 (individuals with leprosy 
who did not begin treatment) and periodontitis the most 
prevalent (25%) in Group 1 (individuals who had al-
ready completed the leprosy treatment).
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